Abstract:In this work, we designed novel peptide conjugates with plant-based iridoid and lichen-derived depside derivatives to target the wild-type EGFR (WT) and its mutants, L858R and T790M/L858R/C797S triple mutant. These mutations are often expressed in multiple cancers, particularly lung cancer. Specifically, the iridoids included 7-deoxyloganetic acid (7-DGA) and loganic acid (LG), while the depside derivative was sekikaic acid (SK). These compounds are known for their innate anticancer properties and were conjugated with two separate peptide sequences KLPGWSG (K) and YSIPKSS (Y). These sequences have been shown to target EGFR in previous phage display library screening, although the mechanism is unknown. Thus, we created the di-conjugates for dual targeting and investigated their interactions of the di-conjugates and that of the neat peptides with the kinase domain of EGFR (WT) and the two mutants using molecular docking, molecular dynamics (MD) simulations, and MM-GBSA analysis. Docking studies revealed that the (7-DGA) 2 -K showed the highest binding affinity at − 9.3 kcal/mol with the L858R mutant, while (LG) 2 -Y displayed the highest binding affinity at − 9.0 kcal/mol for the triple mutant receptor. Our results indicated that several of the conjugates interacted with crucial residues of the kinase domain, including ASP855 and THR854 (activation loop), MET793 and PRO794 (hinge region), ARG841 (catalytic loop), and LYS728 and LEU718 of the glycine-rich P-loop. Interestingly, strong hydrophobic interactions were also observed with the C-terminal tail residues, such as PHE997 and ALA1000 as well as with ARG999 for the YSIPKSS peptide and most of the conjugates. The hydroxyl group of the cyclopentane ring and the oxygen of the pyran ring of the (7-DGA) 2 -peptide conjugates contributed to binding particularly in the hinge region, while the peptide components formed an extended structure that bound well into the C-lobe. The (SK) 2 -Y di-conjugate and KLPGWSG peptide formed hydrogen bonds with the SER797 residue of the triple mutant. Overall, our results show that the (7-DGA) 2 -K, di-conjugate, the (7-DGA) 2 -Y di-conjugate, and the neat YSIPKSS demonstrated strong and stable binding with the L858R mutant and the highly resistant triple mutant EGFR, respectively. The novel designed conjugates demonstrate potential for further optimization for laboratory studies aimed at developing new therapeutics for targeting specific EGFR mutant expressing cells.

Innovative diagnostic peptide‐based technologies for cancer diagnosis: focus on EGFR‐targeting peptides

EGFR- and Integrin αVβ3-Targeting Peptides as Potential Radiometal-Labeled Radiopharmaceuticals for Cancer Theranostics

Anti-cancer peptide-based therapeutic strategies in solid tumors

Peptide-Based Strategies for Targeted Tumor Treatment and Imaging

Aptamer-Based Targeting of Cancer: A Powerful Tool for Diagnostic and Therapeutic Aims

Recent advances and applications of peptide–agent conjugates for targeting tumor cells

Challenges for the application of EGFR-targeting peptide GE11 in tumor diagnosis and treatment

Peptide-Mediated Tumor-Targeted Diagnosis and Therapy

Peptides-based therapy and diagnosis. Strategies for non-invasive therapies in cancer

Generation of peptides using phage display technology for cancer diagnosis and molecular imaging

Small Peptide Ligands for Targeting EGFR in Triple Negative Breast Cancer Cells

Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates

Peptide Therapeutics: Unveiling the Potential against Cancer—A Journey through 1989

Design and investigation of novel iridoid-based peptide conjugates for targeting EGFR and its mutants L858R and T790M/L858R/C797S: an in silico study

Peptide-Conjugated Nano Delivery Systems for Therapy and Diagnosis of Cancer

Peptide-Based Therapeutics in Cancer Therapy

RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin–RGD interactions

The Potential Use of Peptides in Cancer Treatment

Application of functional peptides in the electrochemical and optical biosensing of cancer biomarkers

Harnessing molecular probes for imaging of human epidermal growth factor receptor (HER) family

Design and investigation of interactions of novel peptide conjugates of purine and pyrimidine derivatives with EGFR and its mutant T790M/L858R: an in silico and laboratory study